Adial Pharmaceuticals, Inc. (AZR) stock
Close on Nov 11, 2026Market cap $9.22MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $9.22M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$57.80M
- EPS, diluted
- -$11.93
- Book value per share
- -$8.30
- Diluted shares
- 5M
Trading
- Next earnings
- Nov 13, 2026 (estimated, before the open)
- Previous close
- $3.76
- Open
- $3.75
- Day's range
- $3.35 – $3.90
- Volume
- 11,063
- Average volume (20 days)
- 45,176
- Beta (5 years)
- 0.81
- 52-week range
- $1.31 – $8.75
- RSI (14 days)
- 43.3
- Volatility (1 year)
- 111.2%
- Relative volume
- 0.20×
- WACC
- 8.9%
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | AZR | S&P 500 | Difference | AZR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -10.0% | -2.4% | −7.6 pts | ||
| 3 months | -18.6% | -1.2% | −17.4 pts | ||
| Year to date | -36.2% | +12.3% | −48.5 pts | ||
| 1 year | -57.7% | +12.4% | −70.2 pts | ||
| 3 years | -93.5% | +78.8% | −172.3 pts | -59.8% | +21.4% |
| 5 years | -99.8% | +75.2% | −175.0 pts | -72.2% | +11.9% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Adial Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- Results
- Update
- Update
- Results
About Adial Pharmaceuticals
Pharmaceutical Preparations
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for the treatment or prevention of addiction and related disorders. Its primary investigational drug candidate is AD04, a therapeutic agent designed to treat alcohol use disorder (AUD). The company develops this treatment alongside a companion diagnostic genetic test to identify and target patients with specific genotypes. Adial has no approved products and focuses its resources on research, development, and clinical evaluation.
Company profile, executives and historyAdial Pharmaceuticals stock: common questions
What is Adial Pharmaceuticals's stock price?
AZR closed at $3.51 on Nov 11, 2026, down 6.65% on the day. Over the past 52 weeks it traded between $1.31 and $8.75.
What is Adial Pharmaceuticals's market cap?
Adial Pharmaceuticals was worth $9.22M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is AZR's P/E ratio?
Adial Pharmaceuticals lost money over fiscal 2025 (diluted EPS -$11.93), so it has no meaningful P/E ratio.
Does Adial Pharmaceuticals pay a dividend?
No. Adial Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Adial Pharmaceuticals report earnings next?
Adial Pharmaceuticals is expected to report Q3 FY2026 results on Nov 13, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has AZR stock performed over the past year?
Including dividends, AZR returned -57.7% over the past year, against +12.4% for the S&P 500.
How many AZR shares are sold short?
0M shares were sold short at the latest FINRA report, 43.51% of the float, or 4.1 days of average trading volume.
Who are Adial Pharmaceuticals's competitors?
Companies most similar to Adial Pharmaceuticals by business, industry and size include ALT, ADXN, ANL, GHRS, ALZN.
See a number that looks wrong?